RESUMO
Penfluridol, a diphenylbutylpiperidene derivative, is a new long acting neuroleptic, administered orally, once weekly. It is marketed in several European countries and has been used successfully in the treatment of various acute psychoses, for severely ill chronic schizophrenic patients, and as maintenance therapy for chronic schizophrenic patients. The present study was designed to compare, in a double-blind fashion, the efficacy of penfluridol and fluphenazine decanoate in the maintenance therapy of schizophrenic outpatients.
Assuntos
Assistência Ambulatorial , Flufenazina/uso terapêutico , Penfluridol/uso terapêutico , Piperidinas/uso terapêutico , Esquizofrenia/tratamento farmacológico , Adulto , Doença Crônica , Método Duplo-Cego , Avaliação de Medicamentos , Feminino , Flufenazina/administração & dosagem , Flufenazina/efeitos adversos , Humanos , Masculino , Pessoa de Meia-Idade , Penfluridol/administração & dosagem , Penfluridol/efeitos adversos , Escalas de Graduação PsiquiátricaRESUMO
Loxapine succinate, a newly developed neuroleptic drug, was administered to two groups of geropsychiatric patients: (a) 12 with psychosis and organic brain syndrome, and (b) 14 with chronic schizophrenia. After a two-week baseline period, loxapine was given for 12 weeks. The moderate therapeutic effect of loxapine in the "responders" was similar to that of other neuroleptic drugs. The therapeutic dosage range was found to be from 10 to 80 mg daily--about half that used for younger patients. The chief side effects were drowsiness, mild extrapyramidal symptoms, and a slight increase in blood pressure.